Next Issue
Volume 8, September
Previous Issue
Volume 8, March
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.9
0.9
Journals
Hematology Reports
Volume 8
Issue 2
share announcement
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematol. Rep., Volume 8, Issue 2 (May 2016) – 4 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
3 pages, 643 KiB  
Case Report
Refractory Ascites with Liver Fibrosis Developed in Late Phase Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Patients
by Hiroki Hosoi, Kenji Warigaya, Shogo Murata, Toshiki Mushino, Kodai Kuriyama, Akinori Nishikawa, Shinobu Tamura, Kazuo Hatanaka, Nobuyoshi Hanaoka, Yasuteru Muragaki, Shinichi Murata, Hideki Nakakuma and Takashi Sonoki
Hematol. Rep. 2016, 8(2), 6482; https://doi.org/10.4081/hr.2016.6482 - 27 Jun 2016
Cited by 5 | Viewed by 602
Abstract
We report cases of three patients of refractory ascites without other fluid retention that occurred around five months after allogeneic hematopoietic stem cell transplantation (allo- HSCT). All three patients expired and postmortem examinations revealed unexpected liver fibrosis lacking histological evidences of graft-versus [...] Read more.
We report cases of three patients of refractory ascites without other fluid retention that occurred around five months after allogeneic hematopoietic stem cell transplantation (allo- HSCT). All three patients expired and postmortem examinations revealed unexpected liver fibrosis lacking histological evidences of graft-versus-host-disease (GVHD). The three patients showed normal hepatic function and size before transplantation. During their clinical courses, serum biochemistry test showed no elevation of hepatic enzymes and bilirubin; however, imaging studies demonstrated hepatic atrophy at the onset of ascites. One of the liver specimens showed bile obstruction, which could be seen in hepatic damage by GVHD. Although ascites resulting from venoocclusive disease in early phase allo-HSCT is well documented, ascites associated with hepatic fibrosis in late phase allo-HCST has not been reported. Further clinico-pathological studies on similar patients should be required to ascertain refractory ascites associated with liver fibrosis after allo-HSCT. Full article
2 pages, 581 KiB  
Case Report
CD30+ Primary Cutaneous Post-Transplant Lymphoproliferative Disorder with Signet-Ring Cell Features
by Neeta Malviya and Heather Wickless
Hematol. Rep. 2016, 8(2), 6433; https://doi.org/10.4081/hr.2016.6433 - 27 Jun 2016
Cited by 1 | Viewed by 309
Abstract
We report a case of primary cutaneous CD30+ post-transplant lymphoproliferative disorder with an uncommon finding of signet ring cell features in a heart transplant patient. The neoplastic cells were CD4 and CD30 positive, and negative for S-100, pancytokeratin, myeloperoxidase, and CD56. In situ [...] Read more.
We report a case of primary cutaneous CD30+ post-transplant lymphoproliferative disorder with an uncommon finding of signet ring cell features in a heart transplant patient. The neoplastic cells were CD4 and CD30 positive, and negative for S-100, pancytokeratin, myeloperoxidase, and CD56. In situ hybridization for Epstein Barr Virus (EBV) was negative, even though the patient did have EBV viremia. Full article
4 pages, 572 KiB  
Case Report
Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome
by Bradley T. Williamson, Lynda Foltz and Heather A. Leitch
Hematol. Rep. 2016, 8(2), 6480; https://doi.org/10.4081/hr.2016.6480 - 10 May 2016
Cited by 12 | Viewed by 392
Abstract
Autoimmune manifestations (AIM) are reported in up to 10-30% of myelodysplastic syndromes (MDS) patients; this association is not well defined. We present herein a retrospective chart review of single center MDS patients for AIM, a case discussion and a literature review. Of 252 [...] Read more.
Autoimmune manifestations (AIM) are reported in up to 10-30% of myelodysplastic syndromes (MDS) patients; this association is not well defined. We present herein a retrospective chart review of single center MDS patients for AIM, a case discussion and a literature review. Of 252 MDS patients examined, 11 (4.4%) had AIM around MDS diagnosis. International Prognostic Scoring System scores were: low or intermediate (int)-1 (n = 7); int-2 or high (n = 4). AIM were: culture negative sepsis (n = 7); inflammatory arthritis (n = 3); vasculitis (n = 4); sweats; pericarditis; polymyalgia rheumatica (n = 2 each); mouth ulcers; pulmonary infiltrates; suspicion for Behcet’s; polychondritis and undifferentiated (n = 1 each). AIM treatment and outcome were: prednisone +/- steroid sparing agents, n = 8, ongoing symptoms in 5; azacitidine (n = 3), 2 resolved; and observation, n = 1, ongoing symptoms. At a median follow up of 13 months, seven patients are alive. In summary, 4.4% of MDS patients presented with concomitant AIM. MDS should remain on the differential diagnosis of patients with inflammatory symptoms. Full article
2 pages, 508 KiB  
Case Report
Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib
by Navin Jaipaul, Alexander Pi and Zhiwei Zhang
Hematol. Rep. 2016, 8(2), 6417; https://doi.org/10.4081/hr.2016.6417 - 10 May 2016
Cited by 2 | Viewed by 322
Abstract
About 10–15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope. The proteasome inhibitor bortezomib has been used with [...] Read more.
About 10–15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope. The proteasome inhibitor bortezomib has been used with clinical efficacy in treating patients with AL amyloidosis but also implicated as a possible cause of cardiomyocyte injury. We report a case of a 48-year-old man with AL amyloidosis and increased frequency of syncope and cardiac arrest after starting bortezomib. The biologic and clinical plausibility of a heightened risk for cardiac arrest in patients with cardiac AL amyloidosis and history of syncope being treated with bortezomib is a possibility that is not well documented in the medical literature and warrants further investigation. Full article
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Previous Issue
Next Issue
Back to TopTop